The performance of companies tied to Viagra's legacy presents a challenging investment scenario . While the initial boom generated substantial profits , generic copies have significantly impacted market share . Investing in connected pharmaceutical companies now requires a thorough assessment of proprietary safeguards, evolving healthcare trends ,